Mirum Pharmaceuticals bags Canadian nod for LIVMARLI to treat rare liver disorder
LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution
LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution
Vanda strongly disputes the FDA’s reasoning
The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market
The platform aims to serve doctors, consumers, and healthcare facilities by providing AI-assisted clinical decision tools, personalized health insights, and improved diagnostic capabilities
Patients can now get the starting 2.5 mg dose for $299 per month
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
Subscribe To Our Newsletter & Stay Updated